BiotechTube

E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3

Phase 1Completed
0 watching 0 views this week💤 Quiet
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Food Hypersensitivity

Conditions

Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity, Peanut Hypersensitivity

Trial Timeline

Oct 1, 2009 → Oct 1, 2010

NCT ID
NCT00850668

About E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3

E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3 is a phase 1 stage product being developed by Allergy Therapeutics for Food Hypersensitivity. The current trial status is completed. This product is registered under clinical trial identifier NCT00850668. Target conditions include Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity.

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00850668Phase 1Completed

Competing Products

17 competing products in Food Hypersensitivity

See all competitors
ProductCompanyStageHype Score
Milademetan Treatment A + Milademetan Treatment B + Milademetan Treatment CDaiichi SankyoPhase 1
33
E7386EisaiPhase 1
33
AZD7986, oral solution, 1 to 50 mg/mL + Placebo, oral solutionAstraZenecaPhase 1
33
AcalabrutinibAstraZenecaPhase 2
52
esomeprazole/ASA Fixed Dose Combination (FDC)AstraZenecaPhase 1
33
Ligelizumab 120 mg + Ligelizumab 240 mgNovartisPhase 3
77
OmalizumabNovartisApproved
85
Omalizumab InjectionRocheApproved
85
Glucopyranosyl Lipid A (GLA) + Sublingual Immuno Therapy (SLIT) Peanut Extract (PE) + Placebo for GLA + Placebo for SLIT PESanofiPhase 1
32
DupilumabRegeneron PharmaceuticalsPre-clinical
22
linvoseltamab + dupilumabRegeneron PharmaceuticalsPhase 1
32
DupilumabRegeneron PharmaceuticalsPhase 2
51
Sativex + Sativex + Sativex + SativexJazz PharmaceuticalsPhase 1
30
fruquintinibHUTCHMEDPhase 1
28
VolitinibHUTCHMEDPhase 1
28
Viaskin Milk 150 mcg + Viaskin Milk 300 mcg + Viaskin Milk 500 mcg + Viaskin PlaceboDBV TechnologiesPhase 1/2
36
AZD1722 salt tablet + AZD1722 free base tablet + AZD1722 free base tablet + OmeprazoleArdelyxPhase 1
28

Other Products from Allergy Therapeutics

Atripla (r) + Efavirenz + Truvada + Rifampin/isoniazid/pyrazinamide/ethambutol FDC + Rifampin/isoniazid FDC + IsoniazidApproved
80
Doravirine 100 Mg + Integrase strand transfer inhibitors + Tenofovir alafenamide/emtricitabine + tenofovir disproxil fumarate/emtricitabineApproved
80
Sofosbuvir/Velpatasvir (SOF/VEL)Approved
80
Transdermal estradiol gel + Micronized Progesterone + Placebo for estradiol gel + Placebo for micronized progesteroneApproved
80
Efavirenz + Emtricitabine/Tenofovir disoproxil fumarateApproved
80